1. Enhance the cytotoxic activity of CD8+ T against gastric cancer cells via the GPR109A/HOPX axis;2. Up-regulate gastric cancer cell expression of SCFA receptors (GPR109A, GPR43) and antigen-processing genes (e.g., NLRC5, Tap1, Tap2). The gene discussed is FFAR2; the disease is gastric cancer.